Header
 
Login
 

Privatsphäre-Einstellungen

Wir verwenden Cookies auf unserer Website. Einige von ihnen sind unerlässlich, während andere uns helfen, diese Website und Ihre Erfahrungen zu verbessern.

Notwendig Statistik Marketing
Auswahl bestätigen
Weitere Einstellungen

Hier finden Sie eine Übersicht aller verwendeten Cookies. Sie können ganzen Kategorien Ihre Zustimmung geben oder weitere Informationen anzeigen und bestimmte Cookies auswählen.

Alle auswählen
Auswahl bestätigen
Notwendig Cookies
Wesentliche Cookies ermöglichen grundlegende Funktionen und sind für die ordnungsgemäße Funktion der Website erforderlich.
Statistik Cookies
Statistik-Cookies sammeln anonym Informationen. Diese Informationen helfen uns zu verstehen, wie unsere Besucher unsere Website nutzen.
Marketing Cookies
Marketing-Cookies werden von Werbekunden oder Publishern von Drittanbietern verwendet, um personalisierte Anzeigen zu schalten. Sie tun dies, indem sie Besucher über Websites hinweg verfolgen
Zurück

Ihr Suchergebnis

Sie recherchieren derzeit unangemeldet.
Melden Sie sich an (Login) um den vollen Funktionsumfang der Datenbank nutzen zu können.
Sie suchen in allen Bereichen nach dem Autor Moelgaard G.

In der Rubrik Zeitschriften haben wir 4 Beiträge für Sie gefunden

  1. Merken

    Modern Qualification

    Rubrik: GMP / GLP / GCP

    (Treffer aus pharmind, Nr. 12, Seite 1620 (2019))

    Moelgaard G | Gengenbach R

    Modern Qualification / Are you ready for this opportunity together with your suppliers? · Moelgaard G, Gengenbach R · 1Moelgaard Consulting, Lyngby, Denmark und gempex GmbH, Mannheim, Germany
    Qualification and validation are important pharmaceutical project activities, but for more than 30 years most pharmaceutical companies have been overdoing qualification activities documentation. They misinterpret the regulatory requirements at a high cost of both money and time. The FDA issued its first Guideline on Validation in May 1987 [ 1 ]. In short, the guideline lists the principles and practices that are acceptable to the FDA for the process validation of drug products and medical devices; but it does not list the principles and practices that must, in all instances, be used to comply with US law. In this early guide, only ...

  2. Merken

    2025: Pharmaceutical Technology and Manufacturing Solutions for Facilities of the Future

    Rubrik: Leitartikel

    (Treffer aus pharmind, Nr. 12, Seite 1610 (2017))

    Moelgaard G

    2025: Pharmaceutical Technology and Manufacturing Solutions for Facilities of the Future / Moelgaard • Pharmaceutical Technology · Moelgaard G · Moelgaard Consulting, Lyngby, Denmark
    Disruption in the pharmaceutical industry? It may be hard to imagine but many industries have been undergoing disruption of their businesses in the past and even more will in the future. Think typewriters, film cameras, diskettes or paper-based maps as well as many examples of technology-based disruption but can this happen in pharma? Dosage forms have not changed much since the first industrial tablets and the first injectable drugs in the early 1990s. Yet we could be approaching a new revolution in pharmaceutical products that may disrupt the current product portfolio as well as the current manufacturing technologies. We still ...

  3. Merken

    The Need for Agile Facilities in the Future Pharma Reality

    Rubrik: Biotechnologie

    (Treffer aus TechnoPharm, Nr. 05, Seite 250 (2015))

    Munk M | Moelgaard G

    The Need for Agile Facilities in the Future Pharma Reality / Munk and Moelgaard • Need for Agile Facilities · Munk M, Moelgaard G · NNE Pharmaplan GmbH, Bad Homburg
    single-use technology continuous manufacturing biopharmaceutical facilities flexible facilities biotech manufacturing The pharmaceutical industry is going through interesting but also challenging years. Global competition and regulatory requirements are increasing and both recent patent expirations and pressure to reduce the cost of healthcare have become parts of the new pharma reality. Worldwide operations have considerably increased the complexity of supply chains. Meanwhile, next generation therapeutic approaches such as cell and gene therapy entail a complete change in the pharmaceutical industry’s traditional manufacturing paradigm. In order to stay competitive, companies are looking for ways to improve operations without compromising the high standards of ...

  4. Es gibt 1 weitere Treffer zu Ihrer Anfrage[ Alle Treffer dieser Rubrik anzeigen ]